

August 04, 2022

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

#### То

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 BSE Limited Corporate Relationship Department 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

#### Sub: Investor Presentation

Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2022.

Kindly take the same on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

16am beau

Rajesh Shirambekar Head – Legal & Company Secretary

Encl: As above



# **RPG LIFE SCIENCES**

An ��RPG Company

Investors' Presentation Q1 FY23

# Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.


The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the "Company"), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.



# **RPG Life Sciences Overview**

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



#### **Domestic Formulations (DF)**

Develop, manufacture and market branded formulations in India & Nepal

#### International Formulations (IF)

Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across Regulated and Emerging Markets

#### <u>APIs</u>

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category



Leader in Immunosuppressants



6 Leading Text Book Brands




**50+** Markets Presence




**3** Manufacturing Facilities







# **RPG Life Sciences Product Portfolio**



# **Key Financials, Business Highlights & Strategy**



# **Key Highlights of Q1 FY23**



RPGLS continues to grow faster than the market at 20.9%\* vs 6.6% (IPM)\*\*



PBT continues to grow healthy double digit (30%) despite inflationary pressures and rising costs due to geo-political situations



Profit margins' upward trajectory continues – EBITDA margin reaches record 22.5% & PBT margin record 19.5%. Margin expansion across Domestic and International Formulations



Robust performance of Domestic Formulations, contributing to 2/3<sup>rd</sup> of Company business - driven by diligent execution of our 5 strategic priorities - Product portfolio augmentation, Building strategic brands/ assets, Productivity enhancement, Deepening customer coverage and Profitability improvement



While some of the RPGLS iconic brands, being built into strategic assets through diligent life cycle management strategy, are recording consistent growth, New Products and New Therapies continue to contribute significantly (>20%)



International Formulations business also being strengthened by continuous thrust on New Products/Customers/Markets



Company continues to remain debt free with healthy net cashflow generated from operations



Sales health/ hygiene parameters continue to be in healthy zone and consistently improving




People initiatives driving performance culture with focus on happiness

Company wins the Prestigious "CFBP Jamnalal Bajaj Award" for the first time recognizing our value driven business practices

\* Domestic Formulations internal growth (Q1 FY23) |\*\*AIOCD AWACS MAT Jun 22 An Image: Company


# **Company Financial Performance – Profit Margins**

Upward y-o-y Record setting Trajectory continues – EBITDA Margin reaches 22.5% & PBT Margin 19.5%




All historic numbers are rounded-off to full integers


(All figures in Rs. Crores except EPS in Rs.)



# **Key Financials' Trends**

(All figures in Rs. Crores except EPS in Rs.)






**Company continues to remain Debt-free** 

Domestic Formulations (DF)	<ul> <li>Domestic Formulations contributed 65% to total sales of Q1 FY23</li> <li>21% sales growth majorly driven by legacy products</li> <li>Better than market growth</li> <li>New products contribution improving consistently (currently &gt;20%) on account of new launches in Specialty &amp; Chronic segments and line extensions for legacy products</li> <li>Salesforce productivity improved to &gt;5.0 Lakhs versus 3.4 Lakhs in earlier years</li> </ul>	<u>Sales (Rs Crs)</u> 68.7 <u>22%</u> 83.0	
		FY22 Q1	FY23 Q1

## International **Formulations** (IF)

- International Formulations contributed 19% to total sales of Q1 FY23 ٠
- Robust recovery in IF with sales growth of 24% ٠
- New Products/Customers/Markets contribution continues to improve (currently >30%) ٠

19.5



API

#### API contributed 16% to total sales of Q1 FY23 ٠

- 9% sales growth majorly driven by niche products ٠
- Continuous thrust on new customer development

\*Launched FY19 Onwards

An **RPG** Company

11

# Long term rating reaffirmed at A Short term rating reaffirmed at A1

# **Outlook on long term rating has been retained as Stable**


#### The rating reaffirmation factors:

- Strong brands in the Indian Pharmaceutical Industry
- Considerable improvement in the operating performance on the back of
  - Improvement in sales hygiene
  - Cost rationalisation measures adopted since FY20
- > A robust capital structure and strong coverage indicators based on
  - Decline in the company's debt levels
  - Healthy cash flows
  - No major debt-funded capital expenditure (capex)
- > Expansion of product portfolio and geographical presence augur well for growth prospects

# **Domestic Formulations (DF)**

- Operating in Mass/Mass-specialty and Specialty segments •
- Presence in both Acute & Chronic therapy areas ٠
- Leading Text Book Brands Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace •
- Leading player in Immunosuppressant category •
- Good Customer Coverage Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists •
- New Product Launches in New Category Biosimilars as well as Chronic and Specialty segments .

#### **Business Strategy**




# International Formulations (IF)

- Strong presence in immunosuppressant segment (Azathioprine)
- Footprints across Regulated and Emerging Markets Canada, UK, Germany, France, Australia, South East Asia, Africa
- Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world
- High quality and process orientation making us a preferred partner
- Investments in plant upgradation and capacity expansion

### **Business Strategy**



- High value, low volume, niche APIs
- Mature stable molecules
- Provides backward integration to International Formulations business
- Footprints across geographies LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc.
- Strong customer focus long lasting relationship with big pharma and leading generic firms.



PPG I IFF SCIE

#### **Business Strategy**

# **Infrastructure & Backend Capabilities**



# **Manufacturing Facilities**

#### Formulations Unit 1, Ankleshwar



- F1 unit caters to the domestic and emerging markets
- Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder
- WHO, Kenya, Nigeria approved

Formulations Unit 2, Ankleshwar



- F2 unit caters to the regulated markets
- Dedicated product lines for oral dosage (capsules & tablets)
- Equipped to handle low RH and low temperature conditions products
- WHO, EUGMP (from Hamburg Health authority), Canada, Ethiopia, Kenya, Sudan, Nigeria approved

API Unit, Navi Mumbai



- MF1: Multipurpose unit catering to emerging markets including India
- MF2: Dedicated immunosuppressant facility catering to regulated and emerging markets including India
- MF3: Multipurpose unit catering to regulated and emerging markets including India
- WHO, TGA Australia approved & Written Confirmation (WC) received from CDSCO

An 🆇 RPG Company

# **Strong Backend Capabilities**

# <u>Quality</u>

- All critical SOPs harmonized through CQA
- Quarterly internal audit of all plants by CQA
- All critical deviations, change controls and market complaints investigation approved by CQA

## **Regulatory**

- Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and emerging markets
- Expertise of eCTD submissions
- Integrated project management activities



# Formulations R&D

- In addition to Formulations Development of IR, have capabilities to develop modified release & complex generics
- Dossiers gap analysis and fulfilment
- Tech transfer/site transfer activities
- **GLP compliant analytical lab** for Development and Validation of Analytical Methods

# **Digitalisation Focus Areas**

- Quality Management systems : e-QMS, e-DMS, e-LMS.
- Access to critical manufacturing equipment through IRIS scanner
- All QC instruments attached with **dedicated software** and server
- All stability chambers with software control
- Secondary packing Complies with EUFMD requirement for Track and Trace.



# **Operational Highlights**



A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients.

Our plants did not stop even for a single day in any of the COVID waves Every patient, who asked for our critical medicines, serviced by door delivery.

**100%** Employees are vaccinated with Both Doses

# **Key Priorities**

Employees Care

- Strict protective measures across all locations
  - Detailed SOP
  - Immunity boosting measures
  - Special care for co-morbidities
  - Enhanced medical Insurance
  - Advisories/sessions
  - PPE kits, masks and sanitizers
- Continuous digital connect/engagement with employees and their families



Business Continuity

#### **Conserve Cash**

- Sustained OPEX control measures
- Company continues to be debt-free

#### **Supply Continuity**

• RM/PM availability through proactive planning and relationship management with key vendors

#### **Customer Outreach through Digital**

 Deployment of Digital initiatives like e-CMEs, teleconsultation facilitation service, webinars, etc.




**Community Service** 

- "SafeSeniors" tool development for early detection of risk in vulnerable Senior citizen segment
- Community Servicing through RPG
   Foundation sanitizers, masks, gloves,
   PPE kits; meals, etc.



### **Game Changer Customer Connect Initiative**



### **Employee Connect Initiatives**

 $\mathbf{R}\mathbf{R}\mathbf{2.0}$ 

**Digital Platform for comprehensive** Salesforce Operations tracking:

#Customer visits, customer engagement activities, sales performance analytics etc



**HR Chatbot** for quick resolution of queries related to HR process and company policies



A digital platform for **Salesforce Grievance** Redressal

**P2G** I IFF SCIENCES

#### Initiatives in Plant Operations

**e-QMS**: Digital platform to track all 6 guality parameters

e-DMS: Digital platform to manage all manufacturing/quality documents


e-LMS: Digital platform to track training sessions on CGMP

e- Access: Retina scanning for machine access

All above represent Illustrative list of the initiatives An **RPG** Company

21

# **People Initiatives to build Performance Culture with focus on Happiness**





**P2G** I IFF SCIENCES

# **FY23** Priorities



Maintain growth momentum in top-line and bottom-line across the business segments



Continue to grow our presence in chronic and specialty therapies in DF through new product launches and new customer segments



Continue to build iconic/legacy brands into strategic assets



Continue to enhance salesforce productivity through targeted measures



New customer acquisitions in IF and APIs businesses



Accelerate digital transformation initiatives across frontend and backend to transform business



Continue to implement all initiatives pertaining to strategic priorities identified in our transformation agenda across all three business segments



Building a Happy and Performance driven culture

# **Awards & Recognitions**



# **RPG Lifesciences Awarded with 'Jamnalal Bajaj Award for Fair Business Practices'**



15<sup>th</sup> April 2022 **Industry Recognition to RPG Life Sciences Best Corporate Citizen Award Best Patent Award** CTURERS **SINCE 1961** YEAR IDMA MARGI PATEL CHOKSI MENORIAL BEST RD CATEGORY : PATENT APPRECIA N AWAR IPE STORE





- Ranked 85 amongst India's 100 Best Companies to Work For 2020
- One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work<sup>®</sup> Institute







An **《》RPG** Company